Advertisement

Topics

Companies Related to "begins testing Ebola treatment early stage trial" [Most Relevant Company Matches] RSS

20:57 EDT 19th October 2018 | BioPortfolio

Here are the most relevant search results for "begins testing Ebola treatment early stage trial" found in our extensive corporate database of over 50,000 company records.

Showing "begins testing Ebola treatment early stage trial" Companies 1–25 of 6,400+

Relevant

TFF Pharmaceuticals, Inc.

TFF Pharmaceuticals, Inc. is an early-stage biopharmaceutical company focused on the development and commercialization of new inhalation products for the treatment of chronic respiratory diseases and lung conditions. In early testing the Thin Film Freezing (TFF) proprietary platform significantly improved the solubility of drugs that have poor water solubi...


Medivation, Inc.

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer, Inc to develop an...

HST Global, Inc.

HST Global, Inc. is an Integrated Biotechnology Health and Wellness company that is developing and or acquiring a network of Wellness Centers worldwide that are primarily focused on the immunotherapy and alternative treatment of late stage cancer. In addition, the company intends to acquire innovative products for the treatment of late stage cancer. In thi...


Propel Technology

PROPEL is a group of programs aimed at increasing the number and success rate of early-stage life sciences companies in Illinois. PROPEL helps guide the development of formation-stage and early-stage life sciences companies by providing entrepreneurs with access to specialized resources and expertise to prepare them for early-stage funding. PROPEL is a Cen...

Clinical Assistance Programs

Clinical Assistance Programs (CAP) is a clinical trial management organization. CAP provides site and data quality management, investigator training, and specialized compliance services to life science companies engaged in clinical trials.CAP was created to address many of the problems inherent in the clinical trial process such as site variability, data accuracy, investigator compliance, and the ...

Aurinia Pharmaceuticals Inc.

Aurinia is a clinical stage pharmaceutical company focused on the global nephrology market. It is currently enrolling patients in its Phase 2b clinical trial to evaluate the efficacy of its drug, voclosporin, as a treatment for lupus nephritis (“LN”). LN is an inflammation of the kidneys, that if inadequately treated can lead to end-stage renal d...

DOR BioPharma, Inc.

DOR BioPharma, Inc. (DOR) is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. DOR's lead product, orBec(R) (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of GI GVHD, a comm...

Yaupon Therapeutics, Inc.

Yaupon Therapeutics, a privately held, specialty pharmaceutical company, is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). Based upon results of a recently completed trial, Yaupon intends to file a new drug application (...

Soligenix, Inc.

Soligenix, Inc. (Soligenix) is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. Soligenix's lead product, orBec(®) (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of acute ...

Altura Medical, Inc.

Altura Medical, Inc., a privately held early stage medical device company with current headquarters in San Clemente, CA, was founded in 2008. Major venture investors include SV Life Sciences, New Leaf Venture Partners, and Advanced Technology Ventures. Altura Medical is focused on devices and methods for the treatment of aneurysms in the arterial vascular ...

Sesen Bio, Inc.

Sesen Bio, Inc. is a late-stage clinical company advancing next-generation antibody-drug conjugate therapies for the treatment of cancer based on the company’s Targeted Protein Therapeutics platform. The company’s lead program, Vicinium™, also known as VB4-845, is currently in a Phase 3 registration trial, the VISTA Trial, for the treatment ...

Duska Therapeutics, Inc.

Duska Therapeutics, Inc. (Duska) is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging new pharmacology of adenosine triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which by several pharmaceuticals constitute novel therapeutic modalities for t...

Vion Pharmaceuticals

Vion Pharmaceuticals, Inc. is developing novel agents for the treatment of cancer. We have two small molecule anticancer compounds under evaluation in human clinical trials. Our product, Cloretazine® (VNP40101M) is currently being studied for the treatment of acute myelogenous leukemia (AML), including a pivotal Phase 2 trial in elderly de novo poor-risk AML. In addition a trial of Cloretazine® ...

immatics biotechnologies GmbH

"immatics is a biopharmaceutical company from Tuebingen/Germany. With presently 40 employees immatics develops peptide-based therapeutic vaccines for oncology. The most advanced product candidate, IMA901, addresses the unmet medical need in renal cell carcinoma. Based on very encouraging results from a recently completed phase 1 trial, IMA901 will soon be transferred to phase 2 clinical testing. A...

BioTime, Inc. 

BioTime is a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases. The Company’s current clinical programs are targeting three primary sectors, aesthetics, ophthalmology and cell and drug delivery. Its clinical programs are based on two platform technologies: pluripotent cells...

NorDiag ASA

We at NorDiag have developed a novel, proprietary DNA-based technology for cancer testing. We believe our technology will help increase patient participation in cancer screening programmes and hasten the successful launch of new screening programmes. Key benefits to our product Genefec™ are its non-invasiveness, scalability, cost-effectiveness and its accuracy at the early stages of cancer devel...

Neuroptix Corporation

Neuroptix is creating and developing an innovative, non-invasive eye test to assist in the early diagnosis of Alzheimer’s Disease. Neuroptix’s goal is to provide clinicians with a quick, predictive, reliable, inexpensive and widely available test, enabling early diagnosis and treatment. The company maintains an active interest in collaboration wi...

Grid Therapeutics, LLC

Grid Therapeutics is a biotech company based on the innovative platform for discovering and isolating human derived antibodies. Dr Edward F. Patz, Jr, is the co-founder and CEO of Grid, located in Durham, North Carolina. The lead antibody was discovered in exceptional outcome early stage lung cancer patients who did not progress to develop metastasis. ...

Zelos Therapeutics Inc.

Zelos Therapeutics is an emerging private biopharmaceutical development company that is commercializing breakthrough discoveries in parathyroid hormone (PTH) research. The company is developing medications for the treatment of osteoporosis, psoriasis and for enhancing engraftment following stem cell transplantation. During 2005, Zelos Therapeutics experienced a number of significant milestones. Ke...

Okuvision GmbH

Founded by the leaders of Retina Implant AG in 2007, Okuvision GmbH is an innovator in the field of electrical stimulation therapy (EST) for patients with early and intermediate stage retinitis pigmentosa. Building on the lessons learned through the use of Retina Implant’s subretinal implant technology, Okuvision was founded with the goal of testing a...

Clairus Technologies Incorporated

Clairus has three essential teams working in concert throughout the different stages of the commercialization process: the science team, business team and marketing team. The objective of the teams is to select, develop and market technologies that fit within the Clairus niche markets: early stage therapeutics, early stage diagnostics, and platform research tools.

SLIL Biomedical

SLIL Biomedical Corp. is an early-stage drug discovery company, focused on developing new treatments for cancer and other diseases. SLIL has patented technology and a pipeline of potential drugs, the first of which is expected to enter a human clinical trial for cancer in early 2002.SLIL has a strong board and well-qualified management. The Company also has outstanding scientific resources, led by...

Lightlake Therapeutics Inc

Lightlake Therapeutics is an early stage biopharmaceutical company aiming to build a solid platform of pharmacological treatments based on our expertise using opioid antagonists. Other significant developments include the use of an opioid antagonist nasal spray to address binge-eating obesity. A Phase II trial of this product in Helsinki is due to be compl...

Lightlake Therapeutics Inc.

Lightlake Therapeutics is an early stage biopharmaceutical company aiming to build a solid platform of pharmacological treatments based on our expertise using opioid antagonists. Other significant developments include the use of an opioid antagonist nasal spray to address binge-eating obesity. A Phase II trial of this product in Helsinki is due to be compl...

ACT Biotech Inc.

ACT Biotech (www.actbiotech.com) is a San Francisco-based, privately-held biopharmaceutical company focused on the development and commercialization of targeted cancer drugs. The Company's clinical stage pipeline also includes Telatinib, the most selective oral VEGF/PDGFR/KIT inhibitor ever developed. Telatinib is currently being studied in a Phase 2 trial...


More From BioPortfolio on "begins testing Ebola treatment early stage trial"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks